Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Novo Nordisk recently slashed its 2025 sales and operating profit guidance, citing weaker-than-anticipated momentum for key GLP-1 drugs Wegovy and Ozempic in the U.S. market due to persistent compounded alternatives and escalating competition, particularly from Eli Lilly's Mounjaro and Zepbound. This guidance revision, coupled with disappointing CagriSema study results, Medicare's non-coverage of weight-loss drugs, and a CEO transition, has led to NVO's significant year-to-date stock underperformance. Consequently, despite pipeline advancements in rare diseases, the near-term risk/reward profile is skewed to the downside, prompting investors to consider reducing exposure.

Analysis

Novo Nordisk is confronting a confluence of significant headwinds, underscored by a sharp downward revision of its 2025 full-year guidance. The company reduced its sales growth forecast from a 13-21% range to 8-14% and its operating profit growth estimate from 16-24% to 10-16%. This revision is attributed to slowing momentum for its key GLP-1 drugs, Wegovy and Ozempic, particularly in the U.S. market, where sales are being eroded by the persistent use of unregulated compounded alternatives and slower-than-anticipated patient uptake. Compounding these issues is escalating competition, most notably from Eli Lilly, whose drug Zepbound demonstrated superior weight-loss efficacy (20.2% vs. 13.7%) in a head-to-head study and is rapidly gaining market share. Furthermore, LLY's progress with an oral GLP-1 candidate, orforglipron, threatens to disrupt the injectable-dominated market.

Internal challenges are exacerbating the external pressures. The company reported disappointing late-stage data for its next-generation obesity candidate, CagriSema, dampening expectations for a successor to Wegovy. This pipeline setback coincides with a leadership transition as CEO Lars Fruergaard Jørgensen is set to step down. The market has reacted severely, with NVO shares declining 44% year-to-date, significantly underperforming the industry and broader market. This has pushed the stock's valuation to a forward P/E of 11.87x, a steep discount to both its industry peer group (14.28x) and its five-year historical average (29.25x), signaling a sharp deterioration in investor sentiment. While preliminary Q2 results indicated strong top-line growth and the rare disease pipeline shows promise, these factors are overshadowed by the core business challenges, a Zacks Rank #4 (Sell), and a mixed earnings surprise history.

Key Decisions for Investors

• Given the slashed guidance, intensifying competition from Eli Lilly, and internal setbacks including a CEO transition and disappointing pipeline data, investors should consider reducing exposure as the near-term risk/reward profile appears skewed to the downside.
• Closely monitor the market share trends between NVO's Wegovy/Ozempic and Eli Lilly's Zepbound/Mounjaro, as further erosion of NVO's share is a primary risk to future revenue and profitability.
• While the stock's valuation is at a historical and industry discount, this reflects significant fundamental headwinds and downward earnings revisions, suggesting that a valuation-based entry may be premature until there is clear evidence of market stabilization or pipeline success.